Kihealth’s diabetes assay, which measures the earliest biomarker of insulin resistance, is claimed to be the first diagnostic of its kind.

British scientists at Oxford have developed a novel brain scan technique that may identify Alzheimer’s disease far earlier than previously possible — before any visible symptoms emerge. The method ...

Pfizer PFE-3.43%decrease; red down pointing triangle has agreed to pay up to $7.3 billion for weight-loss drug developer Metsera MTSR 1.16%increase; green up pointing triangle in a deal that gets the ...

The U.S. Food and Drug Administration has approved a version of leucovorin made by GlaxoSmithKline, years after the company pulled the drug from consideration when it stopped manufacturing it. The ...

Roche Holding AG will move an experimental obesity shot into late-stage trials next year in a bid to challenge leaders in the booming market for weight-loss medicines. The drug, known as CT-388, ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. Daniel Payne reports on how the health industry and Washington influence ...

The surreal world of TV pharmaceutical ads, where people with terrible diseases tend to be young, beautiful and living life to the fullest—sometimes with animated monsters—has been parodied on late ...

Readers respond to a guest essay by Keith Humphreys and an article about a fentanyl death. To the Editor: Re “Forced Drug Treatment Isn’t Horrific. It’s a Relief,” by Keith Humphreys (Opinion guest ...

White House officials are considering launching a website that would allow Americans to purchase cheaper prescription drugs directly from pharmaceutical companies, according to a report from Bloomberg ...

President Trump has ordered Arleigh Burke-class guided-missile destroyers to the southern Caribbean, off the coast of Venezuela Sipa USA U.S. Navy/Sipa USA U.S. naval forces have conducted another ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how testing & diagnostics services stocks fared in Q2, starting ...

Today’s leaders face increasingly complex decisions and moral puzzles, often without a clear compass to navigate them. Many are weighing painful cost-cutting measures due to economic uncertainty and ...